RILPIVIRIN - nový nenukleosidový inhibitor reverzní transkriptázy HIV-1
| Title in English | RILPIVIRINE - a novel HIV-i non-nucleoside reverse transcriptase inhibitor |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Klinická mikrobiologie a infekční lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | Rilpivirin; non-nucleoside reverse transcriplase inhibitors; diarylpyrimidine inhibitors; HIV; antiretroviral therapy |
| Description | The arlicle summarizes the basic facts about the pharmacokinetic profile, metabolism and drug interactions of rilpivirine (RPV). This is the latest orally administered second-generation non-nucleoside reverse transcriplase inhibitor (NNRTI) for antiretroviral-naive patients with HIV-1 infection. Conformational flexibility and adaptability are the factors that dominantly determine the high resistance barrier of RPV and are the unique features of diarylpyrimidine inbibitors (DAPY inhibitors - 2nd-generation NNRTIs). Multicentre studies ECHO and THRIVE are also reviewed. Current guidelines for the treatment of HIV/AIDS are mentioned as well as the role of RPV in current therapeutic regiments. |